Resources from the same session
71MO - Randomized phase II study of adjuvant radiotherapy after curative resection of hepatocellular carcinoma with narrow margin (≤1 cm) (RAISE)
Presenter: Ming Kuang
Session: Mini Oral session: Gastrointestinal tumours
Resources:
Abstract
Slides
Webcast
LBA1 - A phase II clinical trial to study the efficacy of cabozantinib in patients with hepatocellular carcinoma refractory to immune checkpoint inhibitor-based treatment
Presenter: Stephen Chan
Session: Mini Oral session: Gastrointestinal tumours
Resources:
Abstract
Slides
Webcast
72MO - Clinical outcomes and response (R) with atezolizumab plus bevacizumab (AB) or lenvatinib (L) in hepatocellular carcinoma (HCC)
Presenter: Mara Persano
Session: Mini Oral session: Gastrointestinal tumours
Resources:
Abstract
Slides
Webcast
LBA2 - Tislelizumab (TIS) versus sorafenib (SOR) in first-line (1L) treatment of unresectable hepatocellular carcinoma (HCC): The RATIONALE-301 Chinese subpopulation analysis
Presenter: Shukui Qin
Session: Mini Oral session: Gastrointestinal tumours
Resources:
Abstract
Slides
Webcast
73MO - Regorafenib in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in real-world practice in Asia: Final analysis of the prospective, observational REFINE study
Presenter: Masafumi Ikeda
Session: Mini Oral session: Gastrointestinal tumours
Resources:
Abstract
Slides
Webcast
Invited Discussant 71MO, LBA1 72MO, LBA2 and 73MO
Presenter: David Tai
Session: Mini Oral session: Gastrointestinal tumours
Resources:
Slides
Webcast
Q&A and discussion
Presenter: Rashid Lui
Session: Mini Oral session: Gastrointestinal tumours
Resources:
Slides
Webcast
LBA3 - Tumor Treating Fields (TTFields) therapy plus XELOX chemotherapy for front line treatment of advanced unresectable gastroesophageal junction adenocarcinoma (GEJC) or gastric adenocarcinoma (GC): A multicenter phase II trial
Presenter: Jin Li
Session: Mini Oral session: Gastrointestinal tumours
Resources:
Abstract
Slides
Webcast
74MO - HERIZON overall survival results: A study of IMU-131, a HER2 targeting peptide vaccine, plus standard of care chemotherapy in patients with HER2 overexpressing metastatic or advanced gastric/GEJ cancer
Presenter: Marina Maglakelidze
Session: Mini Oral session: Gastrointestinal tumours
Resources:
Abstract
Slides
Webcast
75MO - Health-related quality of life (HRQoL) in FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer (G/GEJC): Results from the FIGHT trial comparing bemarituzumab (BEMA) + modified FOLFOX6 (mFOLFOX6) to placebo (PBO) + mFOLFOX6
Presenter: Kensei Yamaguchi
Session: Mini Oral session: Gastrointestinal tumours
Resources:
Abstract
Slides
Webcast